Company: NIVFW
Filing Date: 2025-05-01
Form Type: F-1/A
Source: 0001213900-25-038045
Chunk: 36

Company: NewGenIvf Group Ltd
Filing Date: 2025-05-01
Form: F-1/A
Chunk 36
---
 Shares that we may elect to make to White Lion pursuant to the White                                            
 Lion Purchase Agreement. In addition, we may receive proceeds from conversion of the Additional Notes, the Exchange Notes, the Warrants                                          
 and the New CB Initial Note. All proceeds from the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial                                                  
 Note and the sales of Class A Ordinary Shares to White Lion will be used for working capital and other general corporate purposes.                                               |
| Risk factors                                  |     | You should read the “Risk Factors” section starting on page 25 of this prospectus for a discussion of factors to consider carefully before deciding to invest in our securities. |
| Nasdaq symbol                                 |     | “NIVF” (Class A Ordinary Shares); “NIVFW” (Warrants to purchase Class A Ordinary Shares).                                                                                        |

The number of Ordinary Shares issued and outstanding is 7,508,094 as of April 29, 2025. No new Class A Ordinary Shares will be issued by us under this offering.

24 RISK FACTORS Investing in our Class A Ordinary Shares involves a high degree of risk. You should carefully consider the risks in this prospectus, the risk factors described under the caption “ Risk Factors” in any applicable prospectus supplement and any risk factors set forth in our other filings with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, before making a decision about investing in our Class A Ordinary Shares. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. If any risks actually occur, our business, financial condition and results of operations may be materially and adversely affected. In such an event, the trading price of our Class A Ordinary Shares could decline and you could lose part or all of your investment. Additionally, we are also subject to the following risk factors. Risks Related to NewGenIvf’s Business and Industry We may not be able to continue operating as a going concern. As of December 31, 2024, the Company’s cash and cash equivalents stood at approximately US$457,740. While the Company does not have immediate challenges to settle its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge potential financial and liquidity shortfalls. The Company